University of Michigan Health has been recognized as the top hospital in Michigan, according to U.S. News and World Report’s Best Hospitals Rankings for 2023-24.
It is with great pleasure that we introduce Dr. Annette Kim, Division Director for Molecular and Genomic Pathology and Clinical Professor of Pathology, effective July 1, 2023. Dr. Kim joins us from Brigham and Women’s Hospital (BWH) and Harvard Medical School.
After 12 years of service as the MLabs Medical Director, Jeffrey Myers, M.D., will be focusing on his role as the Vice Chair for Clinical Affairs and Quality in the Department of Pathology and ushering in his MLabs successor, the current MLabs Associate Medical Director, Julia Dahl, M.D.
Dr. Arul Chinnaiyan, S. P. Hicks Endowed Professor of Pathology and Professor of Urology at Michigan Medicine Department of Pathology and Director of the Michigan Center for Translational Pathology, was recently recognized for his outstanding achievements by the American Association of Cancer Research. He was presented with the AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research award at the 2023 AACR Annual Meeting.
The Department of Pathology is pleased to announce Brooklyn Khoury, MBA, MHSA, MS as the new Chief Department Administrator (CDA), effective Monday, June 19, 2023. Ms. Khoury was identified as a top candidate after a comprehensive national search. Khoury will partner with our Department Chair, Dr. Charles Parkos, to manage operations and accomplish strategic initiatives across all our missions.
The American Board of Pathology announced today that our own Dr. Sandra Camelo-Piragua, Professor of Neuropathology and Director of the Neuropathology Fellowship Program, has been selected to serve on the Test Development and Advisory Committee for Neuropathology - a testament to her expertise in the field. The full text of the press release is below. Please join me in congratulating Dr. Camelo-Piragua!
Born and raised in Northeast China, Dr. Xinna Li, Assistant Research Scientist in the Department of Pathology, has always been passionate about helping others. Her journey began with a childhood fascination with medicine. “I remember as a very young child, bandaging a cut on my brother’s leg. Then, as a teen, my cousin became very ill and I observed how medical treatment could cure illnesses. That is when I realized that I wanted to be a doctor,” recounted Li. Driven by the desire to make a difference, she pursued a medical degree in pediatric hematology from China Medical graduating in 1994.
Born and raised in Northeast China, Dr. Xinna Li, Assistant Research Scientist in the Department of Pathology, has always been passionate about helping others. Her journey began with a childhood fascination with medicine. “I remember as a very young child, bandaging a cut on my brother’s leg. Then, as a teen, my cousin became very ill and I observed how medical treatment could cure illnesses. That is when I realized that I wanted to be a doctor,” recounted Li. Driven by the desire to make a difference, she pursued a medical degree in pediatric hematology from China Medical graduating in 1994.
After several decades of hard work by many scientists at the University of Michigan Medical School and elsewhere, an antibody (anti-C5a) has just been approved by the US FDA for treatment of humans who are septic and have developed lung infections with COVID-19, resulting in severe pulmonary dysfunction requiring external lung support. The antibody, anti-C5a, was originally developed in the Dr. Peter Ward laboratory in the early 2000s. The mAb was shown to dramatically reduce lung infections in polymicrobial sepsis in mice.
Idiopathic Pulmonary Fibrosis (IPF) is a disease with unknown causes that result in scarring of the lungs. The scar tissue forms on the alveoli, the small air sacs in the lungs, which makes it more difficult for oxygen to pass through the alveoli walls and into the bloodstream and for carbon dioxide to be removed.